Jump to content

Brontictuzumab

From Wikipedia, the free encyclopedia
Brontictuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetNotch 1
Clinical data
Other namesOMP-52M51
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6392H9862N1980O1710S50
Molar mass143410.36 g·mol−1

Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]

It blocks the NOTCH1 receptor.[3]

This drug was developed by OncoMed Pharmaceuticals.

References

[edit]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brontictuzumab, American Medical Association.
  2. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  3. ^ Cordo' V, van der Zwet JC, Canté-Barrett K, Pieters R, Meijerink JP (January 2021). "T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies". Blood Cancer Discovery. 2 (1): 19–31. doi:10.1158/2643-3230.BCD-20-0093. PMC 8447273. PMID 34661151.